FormFactor Stock Before Q3 Earnings: Smart Buy or Risky Move?

FormFactor expects Q3 2026 EPS of $0.86 ± $0.09 and revenue of $270 million ± $10 million; consensus implies year-over-year growth of 160.6% in EPS and 33.5% in revenue. AI-related probe-card and co-packaged-optics demand, plus an anticipated $7–$9 million in tariff refunds (about 300 bps of gross-margin benefit), are potential supports, but capacity constraints and DRAM mix pose risks. Shares are up 76.6% YTD and trade at 6.54x forward sales versus 5.47x for the sector; Zacks rates the stock Hold pending clarity on margins and capacity.

Analysis

The near-term bar is less about beating the quarter than proving the growth can convert into durable, unassisted margins. At the stated revenue midpoint, consensus is essentially met; a modest EPS beat could be low quality if it relies on the anticipated $7–9 million tariff refund, which the article equates to roughly 300 bps of gross margin. Strip that benefit out when assessing the run-rate, and watch whether DRAM mix and capacity limits absorb the operating leverage from stronger demand.

The market has already capitalized a substantial AI/testing rerating. That makes forward capacity and customer conversion—not another quarter of strong demand—the likely 1–3 month catalysts. CPO revenue claims and XPU design wins matter only if they translate into repeatable production orders and margins; design wins are not equivalent to shipped volume. The Farmers Branch expansion is a 2027 capacity story, so it does not resolve near-term fulfillment constraints. Over 6–18 months, advanced MEMS adoption and higher test intensity are structural positives, but execution and customer concentration remain key risks.

Contrarian angle: consensus may overfocus on the tariff refund and near-term DRAM mix while underweighting the lag between AI demand and deliverable probe-card capacity. Conversely, extrapolating CPO and AI demand straight into valuation ignores that supply, not demand, may cap recognized revenue. COHU, TER and KLAC are not clean valuation or business-model comparables; do not treat their P/S multiples as a direct relative-value signal.

Key Decisions for Investors

• Avoid chasing FORM into the print; consensus already aligns with the company’s midpoint and the share-price rerating leaves limited room for a merely in-line result.
• After earnings, consider a starter long only if management confirms a credible capacity/ramp schedule and underlying gross margin holds up excluding the tariff-refund benefit. Reassess if fulfillment constraints persist or the 2027 ramp slips.
• Track reported DRAM probe-card revenue against the prior-quarter level, CPO shipments versus the stated trajectory, and gross margin excluding refunds; these distinguish durable demand from mix and one-off support.
• No automatic pair trade against COHU, TER or KLAC: their differing product and end-market exposure makes them imperfect hedges. Revisit relative value only with comparable growth, margin and valuation data.